Skip to main content
SpringerLink
Log in

Radiolabeling of zoledronic acid with 188Re as a new palliative agent radiotracer in treatment of bone tumors

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

Zoledronic acid is a bisphosphonates to treat bone problems. Rhenium-188-zoledronic acid could be used as a palliate agent in skeletal metastases. Radiolabeled product was prepared through optimized radiochemical procedures. The organs uptake especially bone uptake assessed in healthy animals mice. The radiochemical purity of the radiotracer was > 95% which was stable up to 24 h. Bone uptake (1.08 ± 0.14% ID/g at 1 h) with retention of activity in bone up to 24 h (0.26 ± 0.06% ID/g) was reached. This radiotracer can be used as a developing candidate for a palliative treatment of bone metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Vincent J, Vigorita MD (2007) Cancer-principles and practice of oncology. Lippincott, Williams & Wilkins, Philadelphia, pp 2713–2729

    Google Scholar 

  2. Mundy GR (2002) Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584–593

    Article  CAS  Google Scholar 

  3. Mantyh PW (2014) The neurobiology of skeletal pain. Eur J Neurosci 39:508–519

    Article  Google Scholar 

  4. Diel IJ (2006) What do patients with metastatic bone pain need? Eur J Cancer Suppl 4(8):1–3

    Article  Google Scholar 

  5. Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017) Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur J Cancer 71:80–94

    Article  Google Scholar 

  6. Sartor O, Hoskin P, Bruland ØS (2013) Targeted radio-nuclide therapy of skeletal metastases. Cancer Treat Rev 39:18–26

    Article  CAS  Google Scholar 

  7. Iwamoto J, Takeda T, Ichimura S (2002) Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 20(4):228–234

    Article  CAS  Google Scholar 

  8. Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(Suppl 4):3–13

    Article  CAS  Google Scholar 

  9. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21(23):4277–4284

    Article  CAS  Google Scholar 

  10. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Bbruzzese A, Lupoli G (2001) Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer 84(12):1586–1590

    Article  CAS  Google Scholar 

  11. Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, Bergstrom B (2004) Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15(5):743–750

    Article  CAS  Google Scholar 

  12. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353(9):898–908

    Article  CAS  Google Scholar 

  13. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321

    Article  CAS  Google Scholar 

  14. Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron DW (2005) Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92(10):1869–1876

    Article  CAS  Google Scholar 

  15. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7(5):377–387

    CAS  Google Scholar 

  16. Lange R, Ter Heine R, Knapp RF, de Klerk JM, Bloemendal HJ, Hendrikse NH (2016) Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. Bone 91:159–179

    Article  CAS  Google Scholar 

  17. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 5ALSYMPCA6 trial. Lancet Oncol 15(12):1397–1406

    Article  CAS  Google Scholar 

  18. Morris MJ, Sartor O, Vogelzang NJ, Shore ND, Cislo P, Bangerter K, Sweeney C (2015) Effect of radium-223 dichloride (Ra-223) on pain from US EAP. J Clin Oncol 33:A160

    Article  Google Scholar 

  19. Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358–1365

    CAS  Google Scholar 

  20. Pillai MRA, Dash A, Knapp FF (2012) Rhenium-188: availability from the 188W/188Re generator and status of current applications. Curr Radiopharm 5:228–243

    Article  CAS  Google Scholar 

  21. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P (2004) Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940–945

    Article  Google Scholar 

  22. Das T, Shinto A, Karuppuswamy Kamaleshwaran K, Banerjee S (2016) Theranostic treatment of metastatic bone pain with 177Lu-DOTMP. Clin Nucl Med 41(12):966–967

    Article  Google Scholar 

  23. Baum RP, Kulkarni HR (2012) THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the bad berka experience. Theranostics 2:437–447

    Article  CAS  Google Scholar 

  24. Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain in Seminars in nuclear medicine. Semin Nucl Med 40(2):89–104

    Article  Google Scholar 

  25. Argyrou M, Valassi A, Andreou M, Lyra M (2013) Rhenium-188 production in hospitals, by W-188/Re-188 generator, for easy use in radionuclide therapy. Int J Mol Imaging 2013:290750

    Article  Google Scholar 

  26. Liepe K, Kropp J, Runge R, Kotzerke J (2003) Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89(4):625–629

    Article  CAS  Google Scholar 

  27. Meckel M, Bergmann R, Miederer M, Roesch F (2016) Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid. EJNMMI Radiophar Chem 1(1):14

    Article  Google Scholar 

  28. Kochetova T, Krylov V, Smolyarchuk M, Sokov D, Lunev A, Shiryaev S, Kruglova O, Makeenkova T, Petrosyan K, Dolgova A, Poluektova M, Galkin V, Kaprin A (2017) 188Re zoledronic acid in the palliative treatment of painful bone metastases. Int J Nucl Medi Res. https://doi.org/10.15379/2408-9788.2017.08

    Google Scholar 

  29. Erfani M, Rahmani N, Doroudi A, Shafiei M (2017) Preparation and evaluation of rhenium-188-pamidronate as a palliative treatment in bone metastasis. Nucl Med Biol 49:1–7

    Article  CAS  Google Scholar 

  30. Janoki GA, Polyak A, Kiraly R, Balogh L, Korosi L, Mathe D (2007) Comparative evaluation of therapeutic radiopharmaceuticals. International Atomic Energy Agency, Vienna

    Google Scholar 

  31. Erfani M, Doroudi A, Dinari MA, Shirmardi SP (2015) Preparation of a rhenium-188 labeled bisphosphonate for bone pain palliation therapy. J Radioanal Nucl Chem 303:2027–2032

    CAS  Google Scholar 

  32. Stenbeck G, Horton MA (2000) A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci 13:1577–1587

    Google Scholar 

  33. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88(6):2095–2105

    Article  CAS  Google Scholar 

  34. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5):617–627

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We like to appreciate Mr. Pezham for providing sodium perrehenate and help through animal study.

Author information

Authors and Affiliations

  1. Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), P.O. Box: 14395-836, Tehran, Iran

    Mostafa Erfani & Mohammad Shafiei

  2. School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, P.O. Box: 61357-33184, Ahvaz, Iran

    Mina Tabatabaei & Alireza Doroudi

Authors
  1. Mostafa Erfani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mina Tabatabaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alireza Doroudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Shafiei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mostafa Erfani.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erfani, M., Tabatabaei, M., Doroudi, A. et al. Radiolabeling of zoledronic acid with 188Re as a new palliative agent radiotracer in treatment of bone tumors. J Radioanal Nucl Chem 316, 491–500 (2018). https://doi.org/10.1007/s10967-018-5781-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-018-5781-9

Keywords

Search

Navigation